Alnylam’s Blood Pressure Drug: Not Exactly Heartwarming Yet
Alnylam just dropped data from their so-called 'investigational therapy' that was supposed to be the Tesla of blood pressure meds but ended up more like a tricycle. Their Phase 2 trial, aka the 'Thrill of Mediocrity,' didn't significantly lower blood pressure. Yet, in a plot twist worthy of a soap opera reboot, the company decided to plunge forward into a late-stage study—because why quit when you can pretend progress? No dollar amounts or dates were shared, but one thing’s clear: Alnylam is writing a new chapter in the 'Lower Your Expectations' saga. If clinical trials were auditions, this one got a polite nod to keep trying.
Share the Story
Alnylam’s blood pressure med didn’t budge the dial, but hey, let’s double down on hope and move to late stage—because who doesn’t love trying the same thing harder until it magically works?
Who knew the secret to clinical success is a solid game of pretend? Alnylam’s drug flopped Phase 2 yet gets a free pass to late stage like it’s the kid who flunked math but still makes varsity cheerleading.
'Significantly lowers blood pressure' took a sick day, but Alnylam’s optimism shows up on time and boots—time to double down on science’s version of 'hold my beer.'
Source: Statnews | Published: 8/30/2025 | Author: Elaine Chen
More Articles in Health
CES 2026: The World’s Largest Tech Flex in the Las Vegas Desert
America Adds 50,000 Jobs, But Those 70,000 Stayed Home for Holidays
Sydney Sweeney's $1M Flop, Trump-Approved Jeans & Bathwater Soap Fiasco
Laura Danger Declares Emotional Labor Is Real Work, Not Invisible Magic
Kennedy’s Protein-Heavy Food Pyramid: Eat More Meat, But Not Saturated Fat, Or Something
Parents Swap 'Because I Said So' For 'Oops, You Bought Too Much Junk'
America Celebrates Lower Gun Deaths While Puffing More Vape Clouds
Trump's Vaccine Makeover: Fewer Shots, More Trust, Same Measles Risks
